![]()
|
|
||||||||
J. Biol. Chem., Vol. 275, Issue 28, 21566-21571, July 14, 2000
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Departments of Pharmacology and
Received for publication, November 23, 1999, and in revised form, April 17, 2000
CD38 is a ubiquitous protein originally
identified as a lymphocyte antigen and recently also found to be a
multifunctional enzyme participating in the synthesis and metabolism of
two Ca2+ messengers, cyclic ADP-ribose (cADPR) and
nicotinic acid adenine dinucleotide phosphate. It is homologous to
Aplysia ADP-ribosyl cyclase, where the crystal structure
has been determined. Residues of CD38 corresponding to those at the
active site of the Aplysia cyclase were mutagenized.
Changing Glu-226, which corresponded to the catalytic residue of the
cyclase, to Asp, Asn, Gln, Leu, or Gly eliminated essentially all
enzymatic activities of CD38, indicating it is most likely the
catalytic residue. Photoaffinity labeling showed that E226G,
nevertheless, retained substantial NAD binding activity. The secondary
structures of these inactive mutants as measured by circular dichroism
were essentially unperturbed as compared with the wild type. Other
nearby residues were also investigated. The mutants D147V and E146L
showed 7- and 19-fold reduction in NADase activity, respectively. The
cADPR hydrolase activity of the two mutants was similarly reduced.
Asp-155, on the other hand, was crucial for the GDP-ribosyl cyclase
activity since its substitution with either Glu, Asn, or Gln stimulated the activity 3-15-fold, whereas other activities remained essentially unchanged. In addition to these acidic residues, two tryptophans were
also important, since all enzyme activities of W125F, W125Y, W189G and
W189Y were substantially reduced. This is consistent with the two
tryptophans serving a substrate positioning function. A good
correlation was observed when the NADase activity of all the mutants
was plotted against the cADPR hydrolase activity. Homology modeling
revealed all these critical residues are clustered in a pocket near the
center of the CD38 molecule. The results indicate a strong structural
homology between the active sites of CD38 and the Aplysia cyclase.
CD38 was first described as a lymphocyte antigen, the expression
of which depends on the stage of differentiation of the lymphocytes (reviewed in Refs. 1 and 2). Mice carrying a null mutation in the CD38
gene exhibit altered humoral immune responses (3). Ligation of CD38
with specific monoclonal antibodies triggers a myriad of responses in
lymphocytes from proliferation to apoptosis (reviewed in Refs. 2, 4,
and 5). Also, increased expression of CD38 on T cells is associated
with human immunodeficiency virus infection, and the expression index
is shown to be the best predictor of shorter survival of the patients
(6, 7).
The biological relevance of CD38, however, is not restricted to
lymphocytes. Its expression has since been found to be widespread among
non-hematopoietic tissues, including the brain (8, 9). In addition to
the antigenic functions, CD38 also possesses a multitude of enzymatic
activities. It is homologous to Aplysia ADP-ribosyl cyclase,
sharing about 30% sequence identity and a perfect alignment of the
cysteine residues (10). Similar to the ADP-ribosyl cyclase, CD38
catalyzes both the cyclization of NAD to cyclic ADP-ribose
(cADPR)1 and a base-exchange
reaction using NADP as substrate, producing nicotinic acid adenine
dinucleotide phosphate (NAADP) (reviewed in Refs. 11 and 12). In
addition, CD38 also catalyzes the hydrolysis of cADPR and NAD. CD38 is
thus catalytically novel. Biologically more relevant, however, are its
two enzymatic products, NAADP and cADPR. Both are Ca2+
messengers mediating the mobilization of intracellular Ca2+
stores in a wide variety of cells from protozoan and plant to human
(reviewed in Refs. 13 and 14). That a single enzyme is capable of
catalyzing the synthesis and metabolism of two structurally and
mechanistically distinct Ca2+ messengers suggests CD38 may
be central to Ca2+ signaling in cells.
In this study, we identify the enzymatic active site of CD38 by
site-directed mutagenesis. We have recently co-crystallized the
Aplysia cyclase with nicotinamide, a substrate of the
base-exchange reaction, and we have characterized its active site by
x-ray crystallography (15). We have taken advantage of the structural
homology between CD38 and the cyclase and have selected four acidic
residues and two tryptophans of CD38 for mutagenesis. These six
residues correspond to those critical residues at the active site of
Aplysia cyclase. The results identified Glu-226 as the most
likely candidate for the catalytic residue.
Expression of the Human CD38 in Yeast--
The Pichia
expression vector pPICZ
The advantages of the X-33 yeast strain have been described previously
(15). Briefly, the strain contains the native alcohol oxidase gene
AOX1, which allows the yeast to metabolize methanol and grow
to higher densities. It also contains the native HIS4 gene,
enabling them to grow without histidine supplementation. The
HIS4 phenotype also allows for use of positive selection
vectors like pPICZ Enzyme Assays--
The wild type or mutant CD38 (0.2-40
µg/ml) was incubated (2 min to 18 h) at room temperature with
various concentrations of specific substrates, 9 µg/ml bovine serum
albumin, 40 mM Tris-HCl, pH 7.8. The total volume of the
reaction mixture was 25-800 µl, and the reaction was stopped by the
addition of sodium dodecyl sulfate (0.2% final concentration). After
diluting to a final volume of 1 ml, 0.8 ml of the mixture was injected
into an AG MP-1 column (10 × 120 mm), and the reaction products
were analyzed by HPLC (Bio-Rad). AG MP-1 was obtained from Bio-Rad. The
elution was performed using a gradient of trifluoroacetic acid at a
flow rate of 5 ml/min as described previously (15). The NAD
glycohydrolase (NADase) and the cADPR hydrolase activities were assayed
with various concentrations of NAD (7-125 µM) or cADPR
(0.16-1.6 mM), respectively. The base-exchange reaction
was similarly assayed at pH 4.5 in the presence of 50 mM
nicotinic acid and various concentrations of NADP (10-160
µM). The GDP-ribosyl cyclase (GDPR cyclase) activity was
measured with 25 µM nicotinamide guanine dinucleotide
(NGD), and the production of cyclic GDP-ribose (cGDPR) was recorded
continuously at the emission wavelength of 410 nm (excitation at 300 nm). The rate of cGDPR production was calculated by differentiating the
time course of the fluorescence change as described previously (20). In
some experiments, GDPR cyclase was also assayed using various [NGD]
(20-1200 µM), and the product, cGDPR, was measured using
HPLC. Enzyme activities of the wild type and mutant CD38 were measured
using at least two different protein preparations. The results shown
were mean ± S.E. of at least four determinations. The
Vmax and Km values were obtained from double-reciprocal plots, and the results shown were mean ± S.E. of at least four determinations.
Site-directed Mutagensis of CD38--
The mutations were carried
out using the QuickChange Site-directed Mutagenesis Kit obtained from
Stratagene. The kit employs the high fidelity PfuTurbo DNA
polymerase and mutant oligonucleotide primers to replicate both strands
of the supercoiled plasmid containing the insert. A mutated plasmid
containing staggered nicks is generated. Following the thermal cycling,
the reaction mixture is treated with DpnI endonuclease that
digests hemimethylated parent DNA leaving behind the nicked DNA
containing the mutation of interest. Plasmid DNA from most
Escherichia coli strains is dam-methylated and
can be digested away with the DpnI enzyme. The procedure
takes 7 days starting from the mutation reaction to transforming
E. coli with the mutated DNA and purifying the resulting
SacI-digested DNA for use in yeast transformation. All
mutations were verified and confirmed by DNA sequencing.
Synthesis of [32P]8-Azido-NAD and Photoaffinity
Labeling--
The details of the synthesis of both the radioactive and
non-radioactive 8-azido-NAD were as we have described previously (15,
23, 24). Droplets (50 µl) of the wild type or mutant CD38 (0.2 µg)
containing 1 µM [32P]8-azido-NAD
(~540,000 cpm), 0-5 mM Homology Modeling of CD38--
The sequence of human CD38 (16)
starting at Pro-53 was first aligned with the sequence of the
Aplysia cyclase (25). The homology feature in Insight II
(Molecular Simulations Inc.) was used, together with the crystal
coordinates of the cyclase dimer that we have previously determined
(15, 26), to generate the homologous structure of the truncated CD38
dimer. This structure was then refined using the using the Powell
relaxation routine in X-PLOR (27). All the cysteines were positioned
close enough that the disulfide bond constraint could be imposed during
the X-PLOR refinement. In the initial homology model, there were 96 bad
contacts and the X-PLOR energy terms for the bonds, angles, dihedrals,
and Van der Waals were 140,000, 27,512, 16,484, and 7.8 × 107, respectively. After refinement, there were no bad
contacts, and the energies were reduced to 243, 1,958, 2,381, and
Circular Dichroism Measurement--
CD38 and its mutants were
purified by cation exchange chromatography as described above. The
purified fractions were pooled and dialyzed against 10 mM
phosphate buffer, pH 7. The dialyzed proteins were concentrated using
Centricon-10 (Millipore) concentrators. All circular dichroism
measurements were done at a protein concentration of 0.5 mg/ml and a
temperature of 25 °C. The samples (125 µl) were added to a 0.05-cm
cuvette, and a Jasco 710 Spectropolarimeter was used to record 6 scans
at 50 nm/min at 0.1-nm intervals from 195 to 250 nm. The 10 mM phosphate buffer used as a blank was subtracted from
each recording. The data were converted to molar ellipticity units and
finally to molar circular dichroism units. Protein concentration was
determined by the method of Scopes (28). The data were calculated by
using the Contin program (29) and are shown as percent We have recently characterized the active site of the
Aplysia ADP-ribosyl cyclase (15). X-ray crystallography
shows that nicotinamide, the substrate of the base-exchange reaction,
is coordinated by three residues, Glu-98, Asn-107, and Trp-140.
Site-directed mutagenesis identifies two additional residues, Trp-77
and Glu-179, at the binding pocket as critical for catalysis. Among
these residues, Glu-179 is most likely to be catalytic. The
corresponding residues in CD38 are Trp-125, Glu-146, Asp-155, Trp-189,
and Glu-226, and they were selected for site-directed mutagenesis.
Additionally, Asp-147 was also targeted. The effects of the mutations
on four enzymatic activities of CD38 were determined. The cyclization reaction was assayed using NGD as substrate, and the production of
cGDPR was monitored fluorimetrically (20). The exchange of the
nicotinamide group of NADP with nicotinic acid was measured as NAADP
production using HPLC (18). The two hydrolytic reactions, NADase and
cADPR hydrolase, were assayed as production of ADP-ribose from NAD and
cADPR, respectively.
The effects of mutagenizing Glu-226, which corresponds to the catalytic
Glu-179 of the cyclase, are shown in Table
I. Substitution of Glu-226 with Leu or
even with conservative residues, such as Asp, Asn, and Gln, totally
eliminated all enzymatic activities. Only residual activities were
detected when substituting with a glycine. This exquisitely specific
requirement of a glutamate residue is consistent with it being the
catalytic residue. We have previously found a similarly high degree of
specificity for a glutamate at the active site of the
Aplysia cyclase (15).
That these substitutions did not induce a gross distortion of the
structure of the active site is shown by the retention of substantial
NAD binding activity of the mutant E226G. The NAD binding activity was
assessed by photoaffinity with [32P]8-azido-NAD in the
absence and presence of increasing concentrations of NAD. Fig.
1 shows that the labeling was specific
for both the mutant, E226G, and the wild type since it was
competitively reduced by NAD. In the case of E226G, the half-maximal
effect was between 0.1 and 0.5 mM of NAD. The intensity of
labeling of the mutant in the absence of NAD was 44% that of the
wild type (inset, Fig. 1).
Identification of the Enzymatic Active Site of CD38 by
Site-directed Mutagenesis*
, and
Physiology,
University of Minnesota, Minneapolis, Minnesota 55455
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
![]()
MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
A (Invitrogen, Carlsbad, CA) was used, and
the construct consisted of cloning the catalytic domain of either the
wild type or mutant human CD38 in frame with the yeast mating
-factor signal sequence. The first 44 residues of CD38, containing
the transmembrane and cytoplasmic domains (16), were deleted, and the
catalytic domain was started at Arg-45. This soluble fragment of the
CD38 has enzymatic activities indistinguishable from the full-length
protein (17-20). The details of the construct were as we have
described previously (19, 21, 22). The tightly controlled alcohol
oxidase promotor AOX1 was used to regulate the expression of
the construct. The X-33 strain of yeast was transfected with the
construct and the expression induced by methanol. The expressed CD38
was secreted as a soluble protein in the medium (19, 21). Endogenous
proteolytic enzymes that normally are responsible for processing the
prepro-
-mating factor also removed the
-factor signal sequence
from the expressed CD38.
A. With this vector the transformation efficiency
was nearly 100%, and no revertants were detected. After a 5-day
induction with methanol in a standard culture tube, the yeast produced
and secreted up to 40 µg/ml of the soluble catalytic fragment of CD38 in the culture medium. After dialyzing the culture media to remove salts, the soluble CD38 proteins were purified in a single step using a
cation exchange column (SP5 PW, Waters, Milford, MA). A linear gradient
of NaCl was used for elution as described previously (19). At least two
separate cultures were made from each mutant, and each culture was
purified separately.
-NAD, and 0.5 mM
-NAD were placed on a piece of parafilm and incubated on ice for
about 0.5-2 min. The droplets were exposed to 100 mJ of
ultraviolet light energy (~70 s) in a Stratalinker chamber
(Stratagene, La Jolla, CA). Pilot experiments showed that this amount
of UV energy produced optimal labeling without detectable
protein-protein cross-linking.
-NAD is not a substrate for CD38 and
was included in all samples to reduce potential nonspecific labeling.
Samples were analyzed by SDS-polyacrylamide gel electrophoresis, and
the radioactivity associated with the proteins was measured using a
PhosphorImager (Packard, Meriden, CT). The phosphorimages were
collected at 16-bit resolution for quantitative analyses but reduced to
8-bit for printout.
365, respectively.
-helix,
-structure, and unordered structure.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
Inhibition of enzymatic activities of CD38 by site-directed mutagenesis
of Glu-226

View larger version (27K):
[in a new window]
Fig. 1.
Photoaffinity labeling of the wild type and
the mutant E226G CD38 using [32P]8-azido-NAD. The
labeled proteins were analyzed by SDS-polyacrylamide gel
electrophoresis, and the radioactivity associated with the proteins was
visualized by a PhosphorImager. The phosphorimages were quantitatively
analyzed at 16-bit resolution but reduced to 8-bit for display in the
inset. The two shaded bars represent the relative
labeling intensity of the wild type (WT) CD38 in the absence
(100%) and presence of 5 mM NAD. The data for E226G at
various [NAD] are represented by filled squares.
The secondary structures of three of the E226 mutants were evaluated
using circular dichroism spectroscopy. The results are listed in Table
II. The percentages of the
-helixes,
-sheets, and random coils of the inactive mutants were essentially
the same as those of the wild type, giving further support that the point mutation at Glu-226 did not induce a gross perturbation on
protein folding.
|
The catalytic role of the conserved sequence near the middle of the CD38 molecule was next investigated. This sequence (Thr-144-LEDTL) is conserved among three species of CD38 and two species of ADP-ribosyl cyclase (reviewed in Refs. 11, 12, and 14). In the Aplysia cyclase, this sequence constitutes the bottom of the active site pocket (15). Glu-146 and Asp-147 are conserved between CD38 and the Aplysia cyclase. Substituting Asp-147 with valine reduced the NADase activity to 17,100 ± 1,500 nmol/mg/min (n = 4, ±S.E.), more than 7-fold reduction as compared with the wild type (cf. Table I). Substituting Glu-146 with leucine depressed the NADase activity even further to 6,600 ± 1,300 (n = 4, ±S.E.), a 19-fold reduction. That these two conserved residues are indeed important for catalysis is further indicated by the total elimination of all enzymatic activities when both residues were substituted (E146L/D147V).
When using NAD as substrate, CD38 mainly hydrolyzes it to ADP-ribose,
and very little cADPR is produced (29-31). The cyclization reaction
catalyzed by CD38 is more easily shown by using NGD, instead of NAD, as
substrate. The main product in this case is cGDPR (20). Although
substitutions of either Asp-147 or Glu-146 decreased the NADase
activity by 7-19-fold, the GDP-ribosyl cyclase activity of the mutants
remained essentially the same as the wild type. The cADPR hydrolase
activity, however, appears to correlate with the NADase activity since
both were correspondingly depressed by the substitutions. This
correlation is further shown in Fig. 2,
where the cADPR hydrolase activity of each mutant was plotted against
its NADase activity. A roughly linear relationship with an
r2 value of 0.93 was apparent. The slope of the
least square line was 2.22, suggesting that the substitutions more
readily affected the cADPR hydrolase than the NADase activity.
|
X-ray crystallography of nicotinamide bound to the active site of the Aplysia cyclase shows that Asn-107 is one of the three closest residues (15). This residue is not conserved in CD38 but corresponds to Asp-155. Table III shows that the most dramatic effect of substituting Asp-155 with a conservative residue, such as Glu, Asn, or Gln, was the large stimulation of the GDP-ribosyl cyclase activity, by as much as 15-fold in the case of D155E. Since all other enzymatic activities of the mutants were only minimally affected, this suggests that Asp-155 is uniquely important for determining the GDP-ribosyl cyclase activity of CD38.
|
In addition to the acidic residues described above, two conserved tryptophans were found to be also important for the enzymatic activities of CD38. Substituting either residue depressed all enzymatic activities uniformly as shown in Table IV. Trp-189 corresponds to the Trp-140 in the Aplysia cyclase, which is responsible for coordinating the bound nicotinamide (15). Its substitution with glycine essentially eliminated all enzymatic activities. A similar decrease in activities was seen even when substituting with tyrosine, another aromatic residue. W189Y showed no NADase nor cADPR hydrolase activities and only residual GDP-ribosyl cyclase, and the exchange activities were detected. Similarly, substituting Trp-125 with similar aromatic residues, phenylalanine and tyrosine, depressed all activities (Table IV).
|
Fig. 3 shows a homology model of CD38.
The crystal coordinates of the dimer of Aplysia cyclase were
used first, which resulted in a model having a number of bad contacts.
After energy minimization, all bad contacts were removed, and the
energy terms showed large reduction, as detailed under "Materials and
Methods." The final homology model of CD38 shows that all 12 cysteines are indeed close enough to form disulfide bonds. This is
consistent with the crystal structure of the Aplysia
cyclase, which shows its 10 cysteines are paired in disulfide bonds
(26). The 10 cysteines of the cyclase are in perfect alignment with
those in the catalytic domain of CD38. The correct placement of the
disulfide bonds lends credence to the homology model. The five
conserved disulfide linkages are represented by purple
cylinders in Fig. 3A, and the extra one is colored
yellow. All the catalytically important residues described
in this study are shown to be in a pocket located close to the middle
of the CD38 molecule. The stereo image in Fig. 3B shows that
Glu-226, which is most likely the catalytic residue, is deep inside the
pocket. Glu-146 and Asp-155, which are important in controlling the
NADase and GDP-ribosyl cyclase activities, respectively, are close
together and positioned opposite to Glu-226. The two critical
tryptophans (Trp-189 and Trp-125) line the rim of the pocket, one on
each side. The Asp-147, which is less important than Glu-146 in
determining the NADase activity, is located farther and slightly away
from the pocket. Also indicated in the Fig. 3 is the location of
Lys-129, which has been shown by a previous study to be important for
the cADPR hydrolase activity (32).
|
| |
DISCUSSION |
|---|
|
|
|---|
The results of site-directed mutagenesis presented in this study identify six residues in the catalytic domain of CD38 as important for the various aspects of catalysis. They span over 100 residues in the CD38 sequence, from Trp-125 to Glu-226, or one-third of the entire domain. There is no a priori reason from the primary sequence to suspect these widely dispersed residues are all important for catalysis. The homology model, however, makes it rather obvious, as all these residues are clustered in a pocket near the middle of the molecule. Two other notable features of the model are as follows: first, the correct placement of Lys-129 at the active site, the mutation of which has previously been shown to inhibit the cADPR hydrolase of CD38 (32); and second, the appropriate pairing of all the cysteines for disulfide linkage. These results indicate that the model is a good representation of the active site of CD38 and that there is a great structural homology between the active sites of CD38 and the Aplysia cyclase. The homology model should thus be a valuable guide for further dissection of the mechanism involved in the novel multifunctional catalysis of CD38.
We have proposed a unified mechanism for the multifunctionality of CD38 and the Aplysia cyclase (11, 14, 33). For the cyclization reaction to occur, the substrate, either NAD or NADP, must bind to the active site in a folded conformation so that the two ends of the molecule can be linked. The pocket structure of the active site as revealed by the homology model should function well in molding the substrate into such a conformation, which is likely to involve stacking of the nicotinamide and adenine groups of the substrate. Indeed, Trp-189, through hydrophobic interaction with either of the stacked aromatic rings, could stabilize such a conformation. That substitution of Trp-189 greatly inhibited all enzymatic activities (cf. Table IV) is consistent with this notion.
The next step in catalysis could be the release of nicotinamide from NAD, with the remaining ADP-ribose forming an activated intermediate. The catalytic residue, Glu-226, most likely would participate in this step. The activated intermediate could be an oxocarbonium ion, as has been proposed for various related enzymes (34-38). The anionic Glu-226 could serve to stabilize the cationic intermediate, as has been shown in both diphtheria and Clostridium botulinum C2 toxins (36, 37). Indeed, we have shown that replacement of the anionic Glu-226 with either an Asn, Gln, or Leu completely eliminated all enzymatic activities (Table I). Substitution with an anionic Asp, however, also inhibited the activities. This could be because the anionic charge of its smaller side chain is too far away from the intermediate to affect ionic stabilization. In addition to Glu-226, two other nearby anionic residues, Glu-146 and Asp-155, could serve a similar stabilization function if the intermediate is able to reorient itself closer to them. Substituting Glu-226 with a glycine, which is essentially equivalent to deletion of its side chain, could provide sufficient room for such reorientation. Indeed, we observed residual activities in E226G.
Intramolecular attack of the intermediate by N-1 of the adenine would result in cyclization and the formation of cADPR from NAD. On the other hand, nucleophilic attack of the intermediate by water would instead lead to hydrolysis and the formation of ADP-ribose from NAD. It has previously been reported that mutation of the two nonconserved cysteines in CD38 can stimulate the cyclase activity (39). The homology model shows that these two cysteines are linked by a disulfide bond at the middle of the molecule. Destruction of the linkage by mutation could lead to significant alteration of the conformation of the active site, restricting water access and thus stimulating the cyclase activity of CD38.
The GDP-ribosyl cyclase activity of CD38 appears to be controlled by Asp-155 (Table III). We have previously shown that cyclization of NGD occurred at N-7 instead of N-1 as in the case of cADPR (33). This would require a rotation of the guanine ring around the N-9-ribose bond to an anti-orientation. Substitutions of Asp-155 with either Asn, Glu, or Gln appear to allow easier rotation of the guanine ring, resulting in stimulation of the GDP-ribosyl cyclase activity. The two hydrolase reactions, NADase and cADPR hydrolase, show significant correlation with respect to residue replacement (Fig. 2). Both reactions could result from nucleophilic attack of the same intermediate by water. The only difference is that whether the same activated ADP-ribosyl intermediate is generated from NAD in one case or from cADPR in the other.
The base-exchange reaction could result from the nucleophilic attack of
the same intermediate by nicotinic acid. The present study presents no
clear indication of which residue could control the access of a
nicotinic residue to the active site. This issue as well as the
verification of the various catalytic features discussed above would
have to be resolved by eventual crystallography of CD38 with various
substrates bound to the active site.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Kevin Mayo for help in the circular dichroism measurements and Malcolm Johns for technical assistance.
| |
FOOTNOTES |
|---|
* This work was supported by National Institutes of Health Grants HD17484 and GM60333 (to H. C. L.) and DA11806 (to T. F. W.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ To whom correspondence should be addressed: Dept. of Pharmacology, 321 Church St. SE, 4-145 Jackson Hall, University of Minnesota, Minneapolis, MN 55455. Tel.: 612-625-7120; Fax: 612-625-0991; E-mail: leehc@tc.umn.edu.
Published, JBC Papers in Press, April 25, 2000, DOI 10.1074/jbc.M909365199
| |
ABBREVIATIONS |
|---|
The abbreviations used are: cADPR, cyclic ADP-ribose; NAADP, nicotinic acid adenine dinucleotide; NGD, nicotinamide guanine dinucleotide; HPLC, high pressure liquid chromatography.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Malavasi, F., Funaro, A., Alessio, M., DeMonte, L. B., Ausiello, C. M., Dianzani, U., Lanza, F., Magrini, E., Momo, M., and Roggero, S. (1992) Int. J. Clin. Lab. Res. 22, 73-80 |
| 2. | Mehta, K., Shahid, U., and Malavasi, F. (1996) FASEB J. 10, 1408-1417 |
| 3. | Cockayne, D. A., Muchamuel, T., Grimaldi, J. C., Mullersteffner, H., Randall, T. D., Lund, F. E., Murray, R., Schuber, F., and Howard, M. C. (1998) Blood 92, 1324-1333 |
| 4. | Malavasi, F., Funaro, A., Roggero, S., Horenstein, A., Calosso, L., and Mehta, K. (1994) Immunol. Today 15, 95-97 |
| 5. | Ferrero, E., and Malavasi, F. (1999) J. Leukocyte Biol. 65, 151-161 |
| 6. | Liu, Z. Y., Cumberland, W. G., Hultin, L. E., Prince, H. E., Detels, R., and Giorgi, J. V. (1997) J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 16, 83-92 |
| 7. | Liu, Z. Y., Hultin, L. E., Cumberland, W. G., Hultin, P., Schmid, I., Matud, J. L., Detels, R., and Giorgi, J. V. (1996) Cytometry 26, 1-7 |
| 8. | Koguma, T., Takasawa, S., Tohgo, A., Karasawa, T., Furuya, Y., Yonekura, H., and Okamoto, H. (1994) Biochim. Biophys. Acta 1223, 160-162 |
| 9. | Yamada, M., Mizuguchi, M., Otsuka, N., Ikeda, K., and Takahashi, H. (1997) Brain Res. 756, 52-60 |
| 10. | States, D. J., Walseth, T. F., and Lee, H. C. (1992) Trends Biochem. Sci. 17, 495 |
| 11. | Lee, H. C. (1999) Biol. Chem. 380, 785-793 |
| 12. | Lee, H. C., Munshi, C., and Graeff, R. (1999) Mol. Cell. Biochem. 193, 89-98 |
| 13. | Lee, H. C. (2000) J. Membr. Biol. 173, 1-8 |
| 14. | Lee, H. C. (1997) Physiol. Rev. 77, 1133-1164 |
| 15. | Munshi, C., Thiel, D. J., Mathews, I. I., Aarhus, R., Walseth, T. F., and Lee, H. C. (1999) J. Biol. Chem. 274, 30770-30777 |
| 16. | Jackson, D. G., and Bell, J. I. (1990) J. Immunol. 144, 2811-2815 |
| 17. | Fryxell, K. B., O'Donoghue, K., Graeff, R. M., Lee, H. C., and Branton, W. D. (1995) Protein Expression Purif. 6, 329-336 |
| 18. | Aarhus, R., Graeff, R. M., Dickey, D. M., Walseth, T. F., and Lee, H. C. (1995) J. Biol. Chem. 270, 30327-30333 |
| 19. | Munshi, C. B., Fryxell, K. B., Lee, H. C., and Branton, W. D. (1997) Methods Enzymol. 280, 318-330 |
| 20. | Graeff, R. M., Walseth, T. F., Fryxell, K., Branton, W. D., and Lee, H. C. (1994) J. Biol. Chem. 269, 30260-30267 |
| 21. | Munshi, C., and Lee, H. C. (1997) Protein Expression Purif. 11, 104-110 |
| 22. | Hussain, A. M. M., Lee, H. C., and Chang, C. F. (1998) Protein Expression Purif. 12, 133-137 |
| 23. | Walseth, T. F., Aarhus, R., Kerr, J. A., and Lee, H. C. (1993) J. Biol. Chem. 268, 26686-26691 |
| 24. | Walseth, T. F., Aarhus, R., Gurnack, M. E., Wong, L., Breitinger, H.-G. A., Gee, K. R., and Lee, H. C. (1997) Methods Enzymol. 280, 294-305 |
| 25. | Glick, D. L., Hellmich, M. R., Beushausen, S., Tempst, P., Bayley, H., and Strumwasser, F. (1991) Cell Regul. 2, 211-218 |
| 26. | Prasad, G. S., McRee, D. E., Stura, E. A., Levitt, D. G., Lee, H. C., and Stout, C. D. (1996) Nat. Struct. Biol. 3, 957-964 |
| 27. | Brunger, A. T. (1992) A System for X-ray Crystallography and NMR, X-PLOR Version 3.1 , Yale University Press, New Haven |
| 28. | Scopes, R. K. (1974) Anal. Biochem. 59, 277-282 |
| 29. | Provencher, S. W. (1982) Comput. Phys. Commun. 27, 213-227 |
| 30. | Howard, M., Grimaldi, J. C., Bazan, J. F., Lund, F. E., Santos-Argumedo, L., Parkhouse, R. M., Walseth, T. F., and Lee, H. C. (1993) Science 262, 1056-1059 |
| 31. | Lee, H. C., Zocchi, E., Guida, L., Franco, L., Benatti, U., and De Flora, A. (1993) Biochem. Biophys. Res. Commun. 191, 639-645 |
| 32. | Tohgo, A., Munakata, H., Takasawa, S., Nata, K., Akiyama, T., Hayashi, N., and Okamoto, H. (1997) J. Biol. Chem. 272, 3879-3882 |
| 33. | Graeff, R. M., Walseth, T. F., Hill, H. K., and Lee, H. C. (1996) Biochemistry 35, 379-386 |
| 34. | Kim, H., Jacobson, E. L., and Jacobson, M. K. (1993) Science 261, 1330-1333 |
| 35. | Muller-Steffner, H. M., Augustin, A., and Schuber, F. (1996) J. Biol. Chem. 271, 23967-23972 |
| 36. | Bell, C. E., and Eisenberg, D. (1996) Biochemistry 35, 1137-1149 |
| 37. | Barth, H., Preiss, J. C., Hofmann, F., and Aktories, K. (1998) J. Biol. Chem. 273, 29506-29511 |
| 38. | Tao, W., Grubmeyer, C., and Blanchard, J. S. (1996) Biochemistry 35, 14-21 |
| 39. | Tohgo, A., Takasawa, S., Noguchi, N., Koguma, T., Nata, K., Sugimoto, T., Furuya, Y., Yonekura, H., and Okamoto, H. (1994) J. Biol. Chem. 269, 28555-28557 |
| 40. | Koradi, R., Billeter, M., and Wuthrich, K. (1996) J. Mol. Graphics 14, 51-55 |
This article has been cited by other articles:
![]() |
F. Malavasi, S. Deaglio, A. Funaro, E. Ferrero, A. L. Horenstein, E. Ortolan, T. Vaisitti, and S. Aydin Evolution and Function of the ADP Ribosyl Cyclase/CD38 Gene Family in Physiology and Pathology Physiol Rev, July 1, 2008; 88(3): 841 - 886. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Jude, M. E. Wylam, T. F. Walseth, and M. S. Kannan Calcium Signaling in Airway Smooth Muscle Proceedings of the ATS, January 1, 2008; 5(1): 15 - 22. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. N. Mutafova-Yambolieva, S. J. Hwang, X. Hao, H. Chen, M. X. Zhu, J. D. Wood, S. M. Ward, and K. M. Sanders beta-Nicotinamide adenine dinucleotide is an inhibitory neurotransmitter in visceral smooth muscle PNAS, October 9, 2007; 104(41): 16359 - 16364. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Liu, I. A. Kriksunov, C. Moreau, R. Graeff, B. V. L. Potter, H. C. Lee, and Q. Hao Catalysis-associated Conformational Changes Revealed by Human CD38 Complexed with a Non-hydrolyzable Substrate Analog J. Biol. Chem., August 24, 2007; 282(34): 24825 - 24832. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Liu, I. A. Kriksunov, R. Graeff, H. C. Lee, and Q. Hao Structural Basis for Formation and Hydrolysis of the Calcium Messenger Cyclic ADP-ribose by Human CD38 J. Biol. Chem., February 23, 2007; 282(8): 5853 - 5861. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Liu, I. A. Kriksunov, R. Graeff, C. Munshi, H. C. Lee, and Q. Hao Structural Basis for the Mechanistic Understanding of Human CD38-controlled Multiple Catalysis J. Biol. Chem., October 27, 2006; 281(43): 32861 - 32869. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Graeff, Q. Liu, I. A. Kriksunov, Q. Hao, and H. C. Lee Acidic Residues at the Active Sites of CD38 and ADP-ribosyl Cyclase Determine Nicotinic Acid Adenine Dinucleotide Phosphate (NAADP) Synthesis and Hydrolysis Activities J. Biol. Chem., September 29, 2006; 281(39): 28951 - 28957. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Deaglio, T. Vaisitti, S. Aydin, E. Ferrero, and F. Malavasi In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia Blood, August 15, 2006; 108(4): 1135 - 1144. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. E. Lund, H. Muller-Steffner, H. Romero-Ramirez, M. E. Moreno-Garcia, S. Partida-Sanchez, M. Makris, N. J. Oppenheimer, L. Santos-Argumedo, and F. Schuber CD38 induces apoptosis of a murine pro-B leukemic cell line by a tyrosine kinase-dependent but ADP-ribosyl cyclase- and NAD glycohydrolase-independent mechanism Int. Immunol., July 1, 2006; 18(7): 1029 - 1042. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. C. Lee Nicotinic Acid Adenine Dinucleotide Phosphate (NAADP)-mediated Calcium Signaling J. Biol. Chem., October 7, 2005; 280(40): 33693 - 33696. [Full Text] [PDF] |
||||
![]() |
D. A. Deshpande, T. A. White, S. Dogan, T. F. Walseth, R. A. Panettieri, and M. S. Kannan CD38/cyclic ADP-ribose signaling: role in the regulation of calcium homeostasis in airway smooth muscle Am J Physiol Lung Cell Mol Physiol, May 1, 2005; 288(5): L773 - L788. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Graeff, C. Munshi, R. Aarhus, M. Johns, and H. C. Lee A Single Residue at the Active Site of CD38 Determines Its NAD Cyclizing and Hydrolyzing Activities J. Biol. Chem., April 6, 2001; 276(15): 12169 - 12173. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||